Oral Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer- Pharmacy Technician

  Price  $6.95

  Credits  2

Clear


Format
Lung cancer claims the lives of more people than any other cancer worldwide. In the US, lung cancer is the third most commonly diagnosed cancer. In 2018, there were approximately 234,030 new cases diagnosed and over 154,000 lung cancer related deaths. Lung cancers are histologically (microscopic tissue structure) defined as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), accounting for 15% and 85% of cases, respectively. Adenocarcinoma is the most common subtype of NSCLC. Because early lung cancer is largely asymptomatic, more than half of the cases have metastasized at the time of diagnosis. The treatment landscape for metastatic lung cancer has changed significantly with the development of targeted oral therapies and immune checkpoint inhibitor (ICPI) therapy. Unlike chemotherapy, targeted oral therapy blocks the growth and spread of cancer cells; not all cells. ICPIs help the immune system distinguish between cancer and normal cells, allowing the immune system to attack the cancer cells. Like most new oncology treatments, ICPIs were initially approved for use later in the sequence of treatment options – but are now standard of care, first-line treatments for some patients. This article will not review ICPIs, but instead focus on the targeted oral therapies available for the treatment of metastatic NSCLC. More patients are receiving longterm, targeted oral therapies due to extended progression-free survival with these medications compared to chemotherapy...
$6.95

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Tech Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • State the genetic mutations or gene rearrangements that a stage IV non-small cell lung cancer patient may have in which a targeted oral therapy is recommended. Recognize the medications that target each specific mutation.
  • List the brand and generic names of the oral targeted therapies discussed in this issue; identify 3 possible side effects of each.
  • Recognize the usual starting dose range for each targeted oral therapy discussed in this issue. List the recommended administration instructions for each.

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    20-878504
  • Universal Activity Number:
    Pharmacy Technician : 0798-0000-21-211-H01-T
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.